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INTRODUCTION: 
Today the tablet is the most popular dosage form of all 
pharmaceutical preparations produced. From the 
manufacturing point of view tablets can be produced at 
much higher rate than any other dosage form1. The 
material used for the production of tablet should be in 
physical form that flows smoothly, directly compressible 
and physically stable so as to achieve rapid production 
capability of tablet formulation. Direct compression is the 
most efficient process used in tablet manufacturing 
because it is the fastest, simplest and least expensive 
tablet-compression procedure. Many processing steps 
mainly granulation and drying are omitted in direct 
compression, and additionally, wet technology cannot be 
used with sensitive agent (e.g., in effervescent tablet 
making).  Direct tableting of pharmaceutical materials is 
desirable to reduce the cost of production. However, 
compressing a drug directly requires good micromeritic 
properties, such as flowability, and a good and 
reproducible compression behavior.  To impart these 
properties the drugs are subjected to particle design 
techniques, spherical crystallization is one the techniques 
of particle design2-4. 
In the pharmaceutical field, Kawashima et al. have given 
impulse to the research of the spherical crystallization 
process. “Spherical crystallization” was defined by 
Kawashima as “an agglomeration technique that 
transforms crystals directly into a compacted spherical 
form during the crystallization process.” Spherical 
crystallization is a particle design technique which is 
restricted to only water insoluble single large dose drugs 
only because several excipients are hydrophilic in nature 
hence addition of these excipients in the agglomerates with 
help of organic bridging liquid is difficult.5 
Kadam et al developed the crystallo-co-agglomeration 
(CCA) technique, which is a modification of spherical 
crystallization. CCA has been designed to overcome the 
limitations of spherical crystallization to obtain directly 
compressible agglomerates. 6,7 Basically, it’s single step 
process used for size enlargement of single, two or more, 
small dose or large dose drugs, in combination with or 
without diluents. The process of CCA involves 
simultaneous crystallization and agglomeration of drug/s 
with/without excipients from good solvent and/or bridging 
liquid by addition of a non-solvent. 8, 9 
The tablet dosage form prepared from agglomerated 
crystals showed improvements in tensile strength, 
hardness, friability, disintegration time and dissolution rate 
as compared to tablets prepared from granules. Thus this 
technique is simple, less expensive, may be an advantages 
for developing it on a commercial scale for manufacturing 
of tablets.10 
METHODS OF SPHERICAL CRYSTALLISATION: 
The methods of spherical crystallization are 
categorized 
Spherical Agglomeration
11
 
A near saturated solution of the drug in the good solvent is 
poured into the poor solvent. Provided that the poor and 
good solvents are freely miscible and the affinity between 
the solvents is stronger than the affinity between the drug 
and the good solvent, crystals will precipitate immediately. 
In the spherical agglomeration method also a third solvent 
called the bridging liquid is added in a smaller amount to 
promote the formation of agglomerates.  Under agitation, 
the bridging liquid (the wetting agent) is added. The 
bridging liquid should not be miscible with the poor 
solvent and should preferentially wet the precipitated 
crystals. As a result of interfacial tension effects and 
capillary forces, the bridging liquid act to adhere the 
crystals to one another. The SA method has been applied 
to several drugs, and it has been found that the product 
properties are quite sensitive to the amount of the bridging 
liquid.  Less than the optimum amount of bridging liquid 
produces plenty of fines and more than optimum produces 
very coarse particles.  Also the choice of bridging liquid, 
the stirring speed and the concentration of solids (or of the 
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solute) are of importance. In the case of lactose, the 
agglomerate size distribution was affected by both the size 
of raw particles and the amount of bridging liquid used. At 
increasing stirring rate the agglomeration was reduced 
because of increasing disruptive forces.  Higher stirring 
rate produce agglomerates that are less porous and more 
resistant to mechanical stress, and the porosity decreases 
when the concentration of solid increases. The viscosity of 
the continuous phase has an effect on the size distribution 
of the agglomerates. The choice of bridging liquid has an 
influence on the rate of agglomeration and on the strength 
of the agglomerates. 
 
 
Figure 1: Showing formation of agglomerates 
Quasi Emulsion Solvent Diffusion Method (QESD)
 11 
In the emulsion solvent diffusion the affinity between the 
drug and the good solvent is stronger than that of the good 
solvent and the poor solvent.  The drug is dissolved in the 
good solvent, and the solution is dispersed into the poor 
solvent, producing emulsion (quasi) droplets, even though 
the pure solvents are miscible. The good solvent diffuses 
gradually out of the emulsion droplets into the surrounding 
poor solvent phase, and the poor solvent diffuses into the 
droplets by which the drug crystallizes inside the droplets. 
The method is considered to be simpler than the SA 
method, but it can be difficult to find a suitable additive to 
keep the system emulsified and to improve the diffusion of 
the poor solute into the dispersed phase. 
 
 
Figure 2: explaining Emulsion Solvent Diffusion Method 
Ammonia Diffusion Method (AD)
 12
 
In this method, the mixture of three partially immiscible 
solvent i.e. acetone, ammonia water, dichloromethane was 
used as a crystallization system. In this system ammonia 
water acted as bridging liquid as well as good solvent, 
Acetone was the water miscible but a poor solvent, thus 
Drug precipitated by solvent change without forming 
ammonium salt. Water immiscible solvent such as 
hydrocarbons or halogenated hydrocarbons e.g. 
dichloromethane induced liberation of ammonia water. 
 
 
Figure 3: explaining Ammonia Diffusion Method (AD) 
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Neutralization Method
13
 
In this method, the drug dissolved in the good solvent and 
placed in the cylindrical vessel with constant stirring. 
While stirring an aqueous polymer solution and one 
neutral solution was added which neutralize the good 
solvent and crystallize out the drug. Then bridging liquid 
was added drop wise at a definite rate, followed by 
agglomeration of the crystal form of the drug takes place. 
CRYSTAL-CO-AGGLOMERATION TECHNIQUE 
(CCA)
 14 
It is a modification of the spherical crystallization 
technique in which drug is crystallized and agglomerated 
with an excipient or with another drug. This process 
enables design of agglomerates containing two drugs or 
poorly compressible drug in combination with diluents and 
is restricted to water insoluble large-dose drugs only. 
Difference in the physicochemical properties of drug 
molecules and excipient is a major challenge in the 
selection of the solvent system for the Crystal-co-
agglomeration technique. 
Steps involved in Crystal-co-agglomeration technique                                
Drug+ good solvent 
↓agitation 
Bridging liquid (homogenous solution) 
↓added continuous stirring 
Bad solvent/polymeric solution 
↓crystal formation 
Spherical agglomeration 
ADVANTAGES OF CRYSTALLO-CO-
AGGLOMERATION: 
15
 
1. Spherical crystallization technique has been 
successfully utilized for improvement of flowability 
and compressibility of crystalline drug. 
2. This technique could enable subsequent processes such 
as separation, filtration, drying etc. to be carried out 
more efficiently. 
3. By using this technology, physicochemical properties 
of pharmaceutical crystals are dramatically improved 
for pharmaceutical process i.e. milling, mixing and 
tabletting because of their excellent flowability and 
packability. 
4. This technique may enable crystalline form of a drug to 
be converted into different polymorphic form and thus 
attain better bioavailability. 
5. For masking of the bitter taste of drug. 
6. Preparation of microsponges, microspheres and 
nanaospheres, microbaloons, nanoparticles and micro 
pellets as novel particulate drug delivery system. 
FACTORS AFFECTING THE PROCESS OF 
AGGLOMERATION: 
1. Diluents selection  
The use of diluent has been suggested in CCA for size 
enlargement of low dose drugs. Diluent selected must be 
physico-chemically and physiologically inert, and 
inexpensive.16 Moreover, it should be insoluble in the 
aqueous phase to avoid the losses through the 
continuous/external phase. Considering desired attributes, 
talc has been used as a diluent in the development of the 
CCA process. Talc as an excipient/diluent in bead/pellet 
making gets strengthened further. Recently, starch and Na-
starch glycolate has been used in preparation of rapidly 
disintegrating agglomerates of naproxen by the CCA 
process. 17, 18 
2. Solvent system 
The solvent system selection for the CCA process depends 
on solubility and stability of drug/s. Since, majority of 
drugs are soluble in organic solvents and poorly soluble in 
water. Use of organic solvent (relatively nontoxic) has 
been recommended as a good solvent and or bridging 
liquid and water as an external/processing phase (non-
solvent). The bridging liquid should carry out preferential 
wetting of crystals/solids and form liquid bridges during 
the process of agglomeration, and simultaneously, it 
should be immiscible with a non-solvent. If bridging liquid 
is used as a good solvent, it means, it performs dual role of 
a good solvent and bridging liquid. The good solvent used 
should be volatile and immiscible with non-solvent to 
avoid drug loss due to co-solvency.  Amount of bridging 
liquid required can be decided by the trial and error 
method or the ternary phase diagram. It has been observed 
that if addition of bridging liquid becomes inadequate, then 
it leads to generation of smaller size agglomerates with 
more percentage of fines. And, excess addition of bridging 
liquid generates bigger size agglomerates and requires 
more processing time for completion of the agglomeration 
process. 19, 20, 21 
3. Mode and intensity of agitation:  
High speed agitation is necessary to disperse the bridging 
liquid throughout the system. Change in the agitation 
pattern or fluid flow will affect the shape of agglomerates. 
The extent of mechanical agitation and the concentration 
of bridging liquid determine the rate of formation of 
agglomerates and their final size.22 
4. Temperature of the system:  
It has a significant influence on the shape, size and texture 
of the agglomerates. The effect of temperature on spherical 
crystallization is probably due to its effect on the solubility 
of drug substance.22 
5. Residence time: 
It is defined as the time for which agglomerates remain 
suspended in the reaction mixture. Residence time affects 
the strength of agglomerates.23 
USE OF POLYMERS: 
Presence of additives like polymers and surface active 
agents whose surfaces are not similar to the crystal 
surfaces can influence molecular aggregation during 
crystallization. Studies have revealed that crystallization 
and agglomeration of pure drugs shows poor 
compressibility and handling qualities. Addition of 
polymers such as HPMC, PEG and PVP has improved the 
properties of spherical agglomerates. It has been reported 
that PVP improved the micromeritic properties, solubility 
and dissolution rate of spherical crystals. The agglomerates 
prepared using an optimum amount of HPMC has showed 
adequate sphericity and mechanical strength to the 
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agglomerates, whereas its excess addition imparts 
ellipticity and deformation to agglomerates.  PEG causes 
reduction in the interfacial tension between water (external 
phase) and bridging liquid resulting into reduction in the 
force of cohesion between particles leading to generation 
of small size spherical agglomerates. 24, 25 PEG, due to its 
soft and plastic nature, undergoes plastic deformation and 
gives better compressibility to the agglomerates during the 
process of compression. Whereas, EC, due to its high yield 
strength, on crystallization in a non-solvent imparts more 
strength to the agglomerates.  Its solubility in the good 
solvent and bridging liquid (organic solvent) imparts 
higher viscosity to the internal phase and results into 
increased interfacial tension. The increased viscosity 
retards the diffusion of bridging liquid, hampers 
nucleation, crystal formation, and increases the time 
required for completion of the agglomeration process. 
Hence, to get agglomerates having satisfactory sphericity 
and strength, and compacts having adequate tensile 
strength, a combination of HPMC, PEG, and EC has been 
recommended during the crystallo-co-agglomeration 
process. 26, 27 
THE PRINCIPLE STEPS INVOLVED IN THE 
PROCESS OF SPHERICAL CRYSTALLIZATION 
1. Flocculation Zone: 
28-33
 
In this zone, the bridging liquid displaces the liquid from 
the surface of the crystals and these crystals are brought in 
close proximity by agitation; the adsorbed bridging liquid 
links the particles by forming a lens bridge between them. 
In these zones, loose open flocs of particles are formed by 
pendular bridges. 
2. Zero Growth Zone: 
Loose floccules get transferred into tightly packed pellets, 
during which the entrapped fluid is squeezed out followed 
by squeezing of the bridging liquid onto the surface of 
small flocs causing poor space in the pellet of completely 
filled with the bridging liquid. The driving force for the 
transformation is provided by the agitation of the slurry 
causing liquid turbulence, pellet-pellet and pellet-stirrer 
collision. 
3. Fast Growth Zone: 
The fast growth zone of the agglomerates takes place when 
sufficient bridging liquid has squeezed out of the surface 
on the small agglomerates. This formation of large 
particles following random collision of well-formed 
nucleus is known as coalescence. Successful collision 
occurs only if the nucleus has slight excess surface 
moisture. This imparts plasticity on the nucleus and 
enhances particle deformations and subsequent 
coalescence. Another reason for the growth of 
agglomerates size is attributed to growth mechanisms that 
describe the successive addition of material on already 
formed nuclei. 
4. Constant Size Zone: 
In this zone agglomerates cease to grow or even show 
slight decrease in size. Here the frequency of coalescence 
is balanced by the breakage frequency of agglomeration. 
The size reduction may be due to attrition, breakage and 
shatter. The rate determining step in agglomeration growth 
occurs in zero growth zones when bridging liquid is 
squeezed out of the pores as the initial floccules are 
transformed into small agglomerates. The rate determining 
step is the collision of particle with the bridging liquid 
droplets prior to the formation of liquid bridges. The rate is 
governed by the rate of agitation. The strength of the 
agglomerates is determined by interfacial tension between 
the bridging liquid and the continuous liquid phase, contact 
angle and the ratio of the volumes of the bridging liquid 
and solid particles. 
EVALUATION PARAMETERS FOR CRYSTALLO-
CO-AGGLOMERATES: 
1. Micromeritic properties:
 34 
Angle of repose: 
Flow property of the material depends on the particle size, 
shape, distribution, surface texture or roughness, surface 
area and applied force. The angle of repose can be 
determined by using the following equation.                                       
                                           Tan Ө = h/0.5 d 
Where h-height of the pile and d- diameter of the pile 
Values for angle of repose ≤ 30 usually indicate free 
flowing material and angle ≥ 40 suggested a poor flowing 
material. 
Compressibility or Carr’s index: 
The ease with which a material can be induced to flow is 
given by application of compressibility index. 
                                                       I = (1-v/vo)* 100 
Where v = the volume occupied by a sample of the powder 
after being subjected to a standardized tapping procedure 
and vo = the volume before tapping. 
Hausner ratio:  
It is calculated from bulk and tapped densities. 
Hausner ratio = tapped density / bulk density  
Values less than 1.25 indicates good flow (20% Carr’s 
index) and the value greater than 1.25 indicates poor flow 
(33% Carr’s index). If it is between 1.25-1.5 add the 
glident to improve flow.  
2. Mechanical properties:
 35
 
Tensile strength of spherical agglomerates is determined 
by compressing 500 mg of crystals using hydraulic press at 
different forces (kg/cm2) for 1 min. The hardness of each 
compact is measured using Pfizer hardness tester.  
3. Dissolution studies: 
Dissolution of spherical agglomerates is determined by 
using the official dissolution apparatus and comparative 
studies are done for agglomerated crystals and non 
agglomerate. Dissolution rate and bioavailability depends 
on the particle size and density and specific surface area of 
the agglomerated crystals. 
4.  Solubility studies:  
Solubility studies are carried out in distilled water and 
dissolution medium by using Flask shaker method. 
Spherical agglomerated crystals are introduced into a flask 
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containing distilled water and dissolution medium. The 
flasks are shaken for 24 hours at room temperature. The 
filtrates are then diluted with the respective medium and 
content is determined by a suitable analytical method. 
5.  Particle Size and Size Distribution:  
Size of the particle and their distributions can be 
determined by simple sieve analysis with the help of a Ro-
Tap sieve shaker. 
6. Optical microscopy: 
The shape of spherical agglomerates is studied by 
observing them under optical microscope. 
7. Differential scanning calorimeter (DSC):  
DSC measures the heat loss or gain resulting from physical 
or chemical changes within a sample. It is also useful to 
determine thermal degradation, purity, polymorphism and 
drug-excipient compatibility. 
8. X-ray powder diffraction:  
Each diffraction pattern is characteristics of a specific 
crystalline lattice for a given compound. The form of 
crystals in agglomerates is determined by using X-ray 
powder diffraction technique. This is an important 
technique for establishing batch-to-batch reproducibility of 
a crystalline form. 
CONCLUSION: 
The spherical crystallization could shorten the 
manufacturing process in tabletting, so that the cost and 
time of manufacturing of the tablets could be reduced. The 
spherically agglomerated crystals were successfully 
prepared for direct tableting by the spherical 
agglomeration technique. The micromeritic properties of 
agglomerates such as flowability, packability and 
compactibility were dramatically improved, resulting in 
successful direct tableting.  The main factor in the 
improvement of flowability and packability was due to 
their spherical shapes and smooth surfaces.  Therefore, 
from the above it can be concluded that spherical 
crystallization is a tool of particle engineering, which can 
transform the poorly flowable drug powder into spherical 
crystals, those are best suited for direct compression. The 
conversion of poorly flowable powder into spherical 
agglomerates enhances the speed of tableting because of 
elimination of most of steps, which required in the wet 
granulation and in dry granulation process. 
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